These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21529378)

  • 1. Tetherin inhibits prototypic foamy virus release.
    Xu F; Tan J; Liu R; Xu D; Li Y; Geng Y; Liang C; Qiao W
    Virol J; 2011 May; 8():198. PubMed ID: 21529378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of inactive tetherin delGPI mutant inhibits HIV-1 Vpu-mediated antagonism of endogenous tetherin.
    Lv M; Wang J; Zhu Y; Wang X; Zuo T; Liu D; Zhang J; Wu J; Zhang H; Kong W; Yu X
    FEBS Lett; 2013 Jan; 587(1):37-43. PubMed ID: 23201263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
    Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
    PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmembrane interactions of HIV-1 Vpu and tetherin.
    Guo F; Liang C
    Curr HIV Res; 2012 Jun; 10(4):292-7. PubMed ID: 22524177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vpu binds directly to tetherin and displaces it from nascent virions.
    McNatt MW; Zang T; Bieniasz PD
    PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
    Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
    J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
    Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
    Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities.
    Cocka LJ; Bates P
    PLoS Pathog; 2012 Sep; 8(9):e1002931. PubMed ID: 23028328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging role of the host restriction factor tetherin in viral immune sensing.
    Hotter D; Sauter D; Kirchhoff F
    J Mol Biol; 2013 Dec; 425(24):4956-64. PubMed ID: 24075872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells.
    Jolly C; Booth NJ; Neil SJ
    J Virol; 2010 Dec; 84(23):12185-99. PubMed ID: 20861257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu.
    Andrew AJ; Miyagi E; Kao S; Strebel K
    Retrovirology; 2009 Sep; 6():80. PubMed ID: 19737401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.
    Mack K; Starz K; Sauter D; Langer S; Bibollet-Ruche F; Learn GH; Stürzel CM; Leoz M; Plantier JC; Geyer M; Hahn BH; Kirchhoff F
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
    Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
    PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
    Vigan R; Neil SJ
    J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purification of eukaryotic tetherin/Vpu proteins and detection of their interaction by ELISA.
    Lv M; Zhu Y; Wang J; Zhang H; Wang X; Zuo T; Liu D; Zhang J; Wu J; Kong W; Yu X
    Protein Expr Purif; 2013 Oct; 91(2):112-8. PubMed ID: 23916489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function.
    Kluge SF; Sauter D; Vogl M; Peeters M; Li Y; Bibollet-Ruche F; Hahn BH; Kirchhoff F
    Retrovirology; 2013 Mar; 10():32. PubMed ID: 23514615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetherin restricts direct cell-to-cell infection of HIV-1.
    Kuhl BD; Sloan RD; Donahue DA; Bar-Magen T; Liang C; Wainberg MA
    Retrovirology; 2010 Dec; 7():115. PubMed ID: 21184674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
    Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
    Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In COS cells Vpu can both stabilize tetherin expression and counteract its antiviral activity.
    Waheed AA; Kuruppu ND; Felton KL; D'Souza D; Freed EO
    PLoS One; 2014; 9(10):e111628. PubMed ID: 25360760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility.
    Kobayashi T; Ode H; Yoshida T; Sato K; Gee P; Yamamoto SP; Ebina H; Strebel K; Sato H; Koyanagi Y
    J Virol; 2011 Jan; 85(2):932-45. PubMed ID: 21068238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.